Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07527013 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke

Study acronym: RESCUE-BP
StatusNot Yet Recruiting
PhasePhase 3
Started2026-06-01
View on ClinicalTrials.gov ↗

Amendment history

2026-04-17
notable
Study Identification, Study Status, Study Design, Outcome Measures v1
Enrollment reduced: 756 → 544 participants
Secondary endpointsdetails revised at 4 of 12 entries
Study title-9 characters
Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke
2026-04-08
minor
Original filing
3,268 trials monitored
See 122 trials at risk
The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \[mRS\] score 0-2). The study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program. The primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.
Trial Details
NCT Number NCT07527013
Lead Sponsor Beijing Tiantan Hospital
Collaborators: Central Hospital of Dalian University of Technology
Conditions Endovascular Therapy, Acute Ischaemic Stroke, Collateral Circulation, Blood Pressure Management, Prognosis
Enrollment 544 participants
Start Date 2026-06-01
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-22